Halley’s Comet, Covid-19, and the history of ‘miracle’ anti-comet rem – Astronomy Magazine

The experts take the floor

Faced with mounting fear, French authorities askedCamille Flammarion, a trustworthy and popular astronomer, to speak to the public. Flammarion considered the possibility that life on Earth might be extinguished should there be a celestial collision with Halleys comet. Should a sufficient quantity of hydrogen in the comets tail be combined with atmospheric oxygen, all animal life could suffocate in just a few moments.

Flammarion considers the event unlikely due to the scarcity of gas in comet tails a fact that would be confirmed later but he admits uncertainty.

We can admit that we ignore what fate has in store for next May. [] The human race would perish in a paroxysm of universal joy, delirium and madness, probably very enchanted with its fate.

Flammarion, as a respectable scientist, recountsall the known elements in his possession: the facts, arguments, and causes, all accompanied by probability. However, the press echoed the most extraordinary part of his words the possible suffocation of all of humanity and passed over its low probability and its supposedly hilarious effect. Thus informed, the general public became understandably terrified of the potentially lethal effects of the comets passage.

When the comet approached in February of that year, spectroscopic observations at theYerkes observatoryin the United States confirmed thepresence of cyanogen in the tail. Scientists detailed what would happen if the Earths orbit and the tails orbit cross paths: the cyanogen will decompose in the upper atmosphere, eliminating any danger of suffocation. Yet their reassuring conclusions went largely unnoticed by the press and the general public.

Following the dissemination of the information of an imminent danger, the reactions were diverse. Some people began to sell all their worldly possessions to take advantage of the short time remaining. Others risked death by alcohol overdose rather than gas intoxication. Others in the United States caulked their windows in a fruitless attempt to prevent the poisonous gas from entering their homes. In France and Italy, others took refuge in churches, the doors of which remained open during that famous night in May 1910. Several tens of thousands of believers gathered to pray in St. Peters Square. A Hungarianpreferred to commit suiciderather than risk being suffocated.

In this context, charlatans seized the opportunity to sell anti-comet pills, based on sugar and quinine, and even an anti-Halleys comet elixir

Of course, not everyone panicked: Flammarion and other astronomers were invited by Gustave Eiffel to the eponymous tower to observe the comet, and many Parisians took the opportunity tofeast and dance all night. To the surprise of some and the disappointment of others, only a small and faint nucleus was visible, if it was visible at all as we now know, Halleys comet is rarely bright when it passes.

See the article here:

Halley's Comet, Covid-19, and the history of 'miracle' anti-comet rem - Astronomy Magazine

Comets scope in on perfection – KOLR – OzarksFirst.com

MARIONVILLE, Mo. Out in Marionville, the Comets football team is feeling pretty good.

That comes with good reason with their record currently sitting at a perfect 6-0, made even more impressive when compared to last years record of 4-6.

Really the biggest difference for us has just been experience, Marionville Head Coach Paden Grubbs said. We were really young at a lot of important positions last year. We had a lot of new starters as sophomores. Now those sophomores are juniors and as the saying goes our juniors are seniors.

All of us coming together in the weight room, Senior OT/DE Austin White said. Hitting the weight room super hard. I think just the culture of the entire team has just made it a better season for us.

Parker: I think its the dedication coming off a season like that we didnt want to repeat, Senior OT/DE Kelbey Parker said. Hard work in the weight room. It starts here in practice as well. Good practice leads to good games.

The Comets are proving themselves time and time again, most recently with a win over Pierce City, a team who made the regular season undefeated run last year.

Very quality class one team in Pierce City, Grubbs said. We hadnt beaten them since 2014. Then the last two years being back in conference with them theyve dominated us. We talked to the kids all week about to be the best, youve got to beat the best.

It really meant a lot to us, especially not beating them the last four years, Senior LB/TE Kyle Brattin said. Not even scoring a point really. Going out there and once we got that first touchdown we all came together and knew what we could do. We were really excited.

With the win, however, the target on Marionvilles back only grows.

Next to take a shot comes Friday night as a Sarcoxie side thats won its last three games comes to town.

I think it will be a battle, Parker said. They are a decent team. Theyre good, but I think if we keep with them we can pull the win.

We basically want to treat each week like were trying to win a conference championship because thats what were trying to do here, White said.

They remind me a lot of us last year, Grubbs said. Theyre young and theyre starting to learn. Were definitely aware of the potential and the dangers they bring from both offensively and defensively.

More here:

Comets scope in on perfection - KOLR - OzarksFirst.com

Marionville’s one-two punch has the Comets undefeated and ready to make noise in postseason – News-Leader

Autoplay

Show Thumbnails

Show Captions

MARIONVILLE Opposing defenses are forced to play a little game of "pick your poison" every week when going up against Marionville.

Either they can try to shut downdynamic sophomore quarterback Wil Carlton or they can do all they can to stop5-foot-5 tailback Dakota Wilson from running all over them.

Try all the defenses want, but so far, nothing has worked.

Marionville (7-0) continued its resurgence with a 48-12 win over Sarcoxie (3-4) on Friday night.The Comets remain unbeaten after two consecutive four-win seasons.

WEEK 7 HIGH SCHOOL FOOTBALL COVERAGE

Dakota Wilson, of Marionville, runs with the ball during the Comets 48-12 win over Sarcoxie in Marionville, Mo., on Friday, Oct. 9, 2020. The Comets remain undefeated this season.(Photo: Andrew Jansen/News-Leader)

The one-two punch of Carlton and Wilson has the Comets back in the state rankings they were ranked No. 8 in the Class 1 rankings this past week. And it appears, as long as they're there, the Comets are here to stay.

"It's amazing having thatgreat of a pair, " Wilson said. "They don't know who to go for and I don't know how to explain it."

It is difficult to explain how Wilson can be so dominant, but his powerlifting resume might do the trick.

Dakota Wilson, of Marionville, runs with the ball during the Comets 48-12 win over Sarcoxie in Marionville, Mo., on Friday, Oct. 9, 2020. The Comets remain undefeated this season.(Photo: Andrew Jansen/News-Leader)

Wilson, listed at 5-foot-5 and 160 pounds, rushed for 182 yards and three touchdowns on the evening. His first score saw him carry what appeared to be most of the Sarcoxie defense the final 10 yards on a 23-yard run.

"I heard everyone yelling that I had the whole team on my back," Wilson said. "I felt a couple but I didn't know how many were on me, to be honest."

The junior ballcarrier is what head coach Paden Grubbs described as one of the pound-for-pound strongest athletes in the state. It's not an overreaction when you learn that he entered a state weightlifting competition last year and squatted over 400 pounds.

"He's a superb athlete," Grubbs said. "He's got great vision for a little back."

Wil Carlton, of Marionville, stiff arms a defender after intercepting the ball during the Comets 48-12 win over Sarcoxie in Marionville, Mo., on Friday, Oct. 9, 2020. The Comets remain undefeated this season.(Photo: Andrew Jansen/News-Leader)

Next to him in the backfield is Carlton who has been putting up some of the best statistics in southwest Missouri as a sophomore.

Carlton did pretty much everything else for the Comets on Friday night. He rushed for 66 yards and a score, he completed 10-of-14 passes for 88 yards and two touchdowns and he also picked off two passes on defense.

"He'd probably be good at pretty much anything he wanted to do," Grubbs said. "We're really fortunate to have him on our side."

The duo has Marionville in a position to be good for the next several years. Grubbs said he can feel the excitement in the community as well as in the elementary school and junior high with players excited to be Comets in the future.

Marionville defeated Sarcoxie 48-12 in Marionville, Mo., on Friday, Oct. 9, 2020. The Comets remain undefeated this season.(Photo: Andrew Jansen/News-Leader)

With Carlton and Wilson leading the way, the Comets should soar for Friday nights for at least the rest of this year and the next. Perhaps they're paving the way for the Comets to be among the state's best for years to come.

"It is (something special)," Grubbs said. "These kids, we talk to them all the time about being humble and just taking it one game at a time. I know it's a cliche but it's a matter of fact.

"It is special though when you hear people talking about it at the elementary and the coffee shops and it's something to be excited about."

Wyatt D. Wheeler is a reporter and columnist with the Springfield News-Leader. You can contact him at 417-371-6987, by email atwwheeler@news-leader.comor Twitter at@WyattWheeler_NL. He's alsothe co-host of Sports Talk on Jock Radio weekdays from 4-6 p.m.

See the rest here:

Marionville's one-two punch has the Comets undefeated and ready to make noise in postseason - News-Leader

West in beast mode: Lady Comets top East Carter in sweep – The Independent

OLIVE HILL Barring an upset, Thursday night was not West Carters final match on John Hop Brown Court this season. That wasnt going to stop the Lady Comets from playing like it was the last time with their rivals in town.

West Carter used scoring spurts in the first two sets to gain the advantage and finished off the 3-0 (25-15, 25-14, 25-17) sweep of East Carter to earn its 14th win of the season.

This group of girls has been playing together for a long time, West Carter coach Christie Tackett said. They communicate well together, and we just work really hard. We have several good, strong and well-skilled players. They have been doing this for a long time. We are strong up front, and I think we have the best setter in the region.

West Carter has five seniors on the roster. Peyton Steagall has made an impact on the program and had the same effect on the opening set, collecting seven kills. Her team ended the frame scoring 11 of the last 13 points to take the early lead.

I think we all make an impact on the team, Steagall said. It really depends on the game and who is doing good at the time.

I think its our hard work and dedication, she added. I believe that is what makes us so good. We are in (the gym) every day and sometimes we come in on Sundays.

Tackett said Steagalls confidence and demeanor on the court and her calming effect off of it helps her lead.

She is a beast, Tackett said. She is a go-getter. She is the always the one that comes up to me when she can tell that Im nervous and says, Dont worry Christie, we got this. Its that senior experience coming through. She showed it tonight. She didnt have any nerves. She said that we are going to get this done and she meant it.

East Carter (7-3) grabbed a 10-8 lead, its first of the match, in Set 2 after an Alexis Thompson kill. The Lady Comets found another offensive punch with five straight points. Rebecca Stevens had three consecutive aces during the surge and West Carter increased its lead to 2-0.

We came out strong and we remembered that earlier game this season, said Tackett, who referred to a 3-2 win over Lady Raiders earlier this year. We played a little relaxed and we didnt want to do that tonight. When you are playing good teams, you never want to relax. They didnt let up. East Carter is a pretty good ball club.

The Lady Raiders kept fighting in the third set. They shrunk the deficit midway through the frame to 15-13 but could get no closer. Steagall punctuated the victory with a final kill. The force of the shot hit the West Carter (14-2) side of the net but found its way over for the point.

We are a scrappy team, but they get so down on themselves, East Carter coach Jennifer Clark said. They set such high expectations for themselves. They get disappointed when they are not doing well. On the other side of it, there was more that I could have done as a coach to prepare them. I think it falls on my shoulders.

Unofficially, Steagall finished with 12 kills for the Lady Comets. Stevens added eight. Madison Adkins dished out 20 assists. Thompson tallied four kills for the Lady Raiders.

The 16th Region Tournament will be held in Olive Hill and West Carter hopes it will see the home court three more times. Steagall believed the Lady Comets performance on Thursday night was a fitting end for their regular season home finale.

Its bittersweet for me, Steagall said. Its sad that its coming to an end, but I wouldnt want to beat anybody else on this court.

(606) 326-2654 |

msparks@dailyindependent.com

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

See more here:

West in beast mode: Lady Comets top East Carter in sweep - The Independent

Looking for pieces of Venus? Try the moon – Yale News

A growing body of research suggests the planet Venus may have had an Earth-like environment billions of years ago, with water and a thin atmosphere.

Yet testing such theories is difficult without geological samples to examine. The solution, according to Yale astronomers Samuel Cabot and Gregory Laughlin, may be closer than anyone realized.

Cabot and Laughlin say pieces of Venus perhaps billions of them are likely to have crashed on the moon. A new study explaining the theory has been accepted by the Planetary Science Journal.

The researchers said asteroids and comets slamming into Venus may have dislodged as many as 10 billion rocks and sent them into an orbit that intersected with Earth and Earths moon. Some of these rocks will eventually land on the moon as Venusian meteorites, said Cabot, a Yale graduate student and lead author of the study.

Cabot said catastrophic impacts such as these only happen every hundred million years or so and occurred more frequently billions of years ago.

The moon offers safe keeping for these ancient rocks, Cabot said. Anything from Venus that landed on Earth is probably buried very deep, due to geological activity. These rocks would be much better preserved on the moon.

Many scientists believe that Venus might have had an Earth-like atmosphere as recently as 700 million years ago. After that, Venus experienced a runaway greenhouse effect and developed its current climate. The Venusian atmosphere is so thick today that no rocks could possibly escape after an impact with an asteroid or comet, Cabot said.

Laughlin and Cabot cited two factors supporting their theory. The first is that asteroids hitting Venus are usually going faster than those that hit Earth, launching even more material. The second is that a huge fraction of the ejected material from Venus would have come close to Earth and the moon.

There is a commensurability between the orbits of Venus and Earth that provides a ready route for rocks blasted off Venus to travel to Earths vicinity, said Laughlin, who is professor of astronomy and astrophysics at Yale. The moons gravity then aids in sweeping up some of these Venusian arrivals.

Upcoming missions to the moon could give Cabot and Laughlin their answer soon. The researchers said NASAsArtemis programis the perfect opportunity to collect and analyze unprecedented amounts of lunar soil.

Laughlin said there are several standard chemical analyses that can pinpoint the origin of moon rocks, including any that came from Venus. Different ratios of specific elements and isotopes offer a kind of fingerprint for each planet in the solar system.

An ancient fragment of Venus would contain a wealth of information, Laughlin said. Venus history is closely tied to important topics in planetary science, including the past influx of asteroids and comets, atmospheric histories of the inner planets, and the abundance of liquid water.

Read this article:

Looking for pieces of Venus? Try the moon - Yale News

Mustangs, Beavers, Falcons roll to football wins; G’s, Comets fall – Midland Daily News

PINCONNING Meridian spoiled Pinconning's homecoming with a 35-6 win in Jack Pine Conference football on Friday.

The Mustangs got on the board with 3:40 to play in the first quarter when Jake Schultz ran in a 3-yard touchdown. Schultz later added his second TD of the game on a 1-yard run with 11:55 to go in the second quarter.

Brayden Riley punched in a 5-yard touchdown with 9:08 to go in the half, then quarterback Cam Metzger hit Josh Barriger for a 33-yard TD with 1:07 to play. Meridian had a 28-0 lead at the break.

Early in the fourth, Metzger hit Barriger again -- this time for a 14-yard TD -- with 9:47 to play in the game.

The Spartans added a score late and missed the extra point.

Metzger finished 7-of-11 passing for 128 yards and two TDs. Schultz finished the night as the Mustangs' leading rusher with 52 yards on 13 carries and two TDs. Metzger was right behind Schultz with 51 yards on 10 carries.

Barriger was the leading receiver with 54 yards on three receptions and the two TDs. Dane Plichta had 45 yards on one catch.

Josh Nohel was Meridian's leading tackler with 7.5 total tackles (seven solo) including two tackles for loss. Alex Wall added four tackles (three solo).

Meridian kicker Gabe Mutai made all five of his extra point attempts.

"Tonight was great because we were able to get everyone in for a lot of reps," said Mustangs' coach Mike Bilina. "They work their butts off and we were able to reward them by getting them in tonight."

Meridian (3-1, 3-1 JPC) hosts Farwell next Friday.

Beaverton 42, Farwell 0

FARWELL -- Noah Coffey and Cam Mishler each ran for two touchdowns in Beaverton's 42-0 win over Farwell in Jack Pine Conference football on Friday.

Coffey ran for scores of 28 yards and 7 yards while Mishler ran for 36-yard and 3-yard scores for the Beavers, who scored all their points in the first half.

Trent Reed ran for a 60-yard score and Beaverton's other TD came on Mitch Hall's 28-yard interception return.

Reed was 4 of 5 on extra points and Coffey ran in a 2-point conversion.

Reed completed 4 of 4 passes for 81 yards and ran seven times for 111 yards and the TD.

Brayde Keeley had one catch for 48 yards.

On defense, Logan Love had six tackles while Mitch Hall and Kyle Hall each made four stops.

"Another good team effort tonight," coach Aaron Seiser said after his Beavers improved to 3-1 overall and in the JPC. "Our defense gave our offense great field position most of the night and we were able to capitalize.

"Another plus was the amount of experience our young players were able to get in the second half. We have a huge game coming up versus our rival (Gladwin). We must have a great week of practice."

The Beavers host the Flying G's next Friday.

Freeland 21, Swan Valley 14

FREELAND Bryson Huckeby took a 5-yard run into the end zone as time expired in the third quarter to give Freeland a 21-14 win over rival Swan Valley in Tri-Valley Conference Central football Friday.

Huckeby's run was his second TD run of the night. The other was an 83-yarder with 8:17 to play in the second quarter. That run put Freeland up 14-0 after Garrett Pistro had punched in a 4-yard TD run late in the first quarter.

Swan Valley scored late in the first half to cut the Falcon lead to 14-6 at the break.

The Vikings then scored with 4:49 to play in the third to tie the game at 14. Huckeby's run put Freeland ahead for good.

Huckeby finished the night as Freeland's leading rusher with 90 yards on eight carries and the two TDs. He was also 6-of-10 passing for 81 yards. Jacob Kundinger had 48 yards on nine carries.

Kundinger led the defense with 12 tackles and a sack. Cole Wiese had 11 tackles. Nolan Vanloo and CJ Schultz each had 10.

Freeland won the Battle of the Mountain Trophy for the first time in three years with the win.

"Just a little added fuel to the fire with the crosstown rivalry," said Falcons' coach Kevin Townsend. "They've had some special squads come through there.

"Bryson got targeted and that was a momentum swinger; the guys rallied around their leader almost going down. Starting safety Alex Duley rolled his ankle early in the fourth quarter. Carter Suppes had an interception. They (isolated) him on their best receiver, another senior stepping up to the challenge."

Freeland (3-1, 2-0 TVC Central) next travels to Bridgeport on Friday.

Clare 41, Gladwin 30

GLADWIN Gladwin dropped a back-and-forth battle against unbeaten Clare 41-30 in Jack Pine Conference football on Friday.

After the Pioneers took a 7-0 lead, Nick Wheeler hit Aaron Kozlow for a 13-yard touchdown pass to make it 7-6 at the end of the first quarter.

After Clare scored again, Wheeler connected with Kaden McDonald for a TD with 12 seconds left in the first half. But a missed two-point conversion left Clare ahead 13-12.

On the ensuing kickoff, Clare returned it 85 yards for a TD to take a 19-12 lead to the break.

With 7:18 to play in the third quarter, Logan Kokotovich carried it in from 15 yards to cut the deficit to 19-18.

Wheeler gave the Flying G's their first lead on a 3-yard run to put Gladwin ahead 24-19 early in the fourth quarter.

Clare scored with 9:35 to play to take a 27-24 lead. But Wheeler connected with McDonald again -- this time on fourth down and from 4 yards out -- to put Gladwin back in front 30-27 with 7:33 to play.

Clare scored twice more within the last 3:30 to take the 11-point victory.

"We allowed too many big plays to happen in the first half," said Flying G's coach Marc Jarstfer. "They came out and received the ball in the second half. We played good defense. We would go down and score, then they would go down and score ...

"Just a good, hard-fought game. Clare has been the team to beat for the better part of two decades. We know they are well-coached and are going to be well-prepared. We just made too many mistakes down the stretch."

No other individual stats were available.

Gladwin (2-2, 2-2 JPC) travels to Beaverton on Friday.

St. Charles 37, Coleman 6

ST. CHARLES -- Coleman's Konner Carbeno had a strong night in the Comets' 37-6 loss to St. Charles in Mid-State Activities Conference football on Friday.

Carbeno had 22 carries for 149 yards and a touchdown.

Conner Schrank added seven carries for 57 yards for Coleman, which trailed 29-6 at halftime.

On defense for the Comets, Jaden Bovee had seven tackles, Schrank made an interception and Ayden Ruhle recovered a St. Charles fumble.

"We came into the game shorthanded and we turned into a MASH unit as the game went on. (Our) young kids got some good reps. We will keep fighting," Coleman coach Chad Klopf said.

The Comets host Montabella next Saturday at noon.

Read the original post:

Mustangs, Beavers, Falcons roll to football wins; G's, Comets fall - Midland Daily News

Comets, Longhorns to square off in Dickson – Daily Ardmoreite

Beau Bearden| bbearden@gannett.com

For the first time since 2017, the Dickson and Lone Grove high school football teams will battle on the gridiron in a district matchup.

However, the squads arent strangers just16 miles separates the two and the Longhorns have won 11 of the past 16 meetings dating back to 2004, with the Comets tallying a victory in 2018.

Lone Grove has played (Dickson) forever either being in the district or non-district, said Longhorns head coach Brad OSteen. Its kind of a rivalry game, being that were so close and everything. This is a big game for both teams.

Thats especially the case as each squad is coming off a district loss. Lone Grove dropped a 28-8 setbackto Kingston last week, while the Comets fell 48-7 to Plainview.

The Longhorns (3-2 overall, 1-1 District 3A-2) sit in a four-way tie for second place with Pauls Valley, Plainview and Madill, while Dickson (0-5, 0-2) isstill looking for its first win of 2020.

However, the Comets have the same mentality after a loss as they would following a victory.

We always call it a 24-hour rule, said Dickson head coach Steve Day. Whether you win or lose, you get 24 hours to move on from it. Even if youre 5-0, its the 24-hour rule. You act like youre 0-0 and competing to win the next game. Thats kind of been our motto or our thought process since Ive been here. Whether you win or lose, you move on from it.

Meanwhile, Lone Grove is likely using the same strategy afterits two-game winning streak came to an end at the hands of Kingston, which is tied for first in the district with Sulphur at 2-0.

The Longhorns trailed the Redskins 7-0 at halftime, but the momentum shifted in the wrong direction during thesecond half.

We caught some breaks in the first half as far as on defense, OSteen said. As far as defensively, we couldnt execute and didnt capitalize on some things. We should have been up 14-7 at halftime. (Kingston) came out and turned it up in the second half and we didnt. We have to learn from that and get better.

The Comets also know they have some areas to improve on, as they struggled to get much going offensively against Plainview.

We go through all of our goals each week for offense, defense and special teams and kind of review it as a team to see which ones we hit and which ones we didnt, and why wedid and didn't hit those goals,"Day said. We try to point out positives and the kids knew it there werent a whole lot of positives with that game.

However, that doesnt mean Dickson doesnt have stars that can make a difference. Johnny Smith and Jzavionn Bennett have caused problems for many teams and Lone Grove knows it.

They have some guys who can play, they have some good athletes, OSteen said of the Comets. This is more about us trying to get better. Obviously, we have to take care of our business against those guys. During a week like this, you just have to go get better, learn from your mistakes and not let them happen again.

Link:

Comets, Longhorns to square off in Dickson - Daily Ardmoreite

In a first, scientists discover comet having own northern lights – India Today

The Rosetta mission of the European Space Agency and the National Aeronautics and Space Administration (Nasa) has discovered a comet which has its own "far-ultraviolet aurora".

The comet named 67P/Churyumov-Gerasimenko - Chury for short - is one of a kind as it is for the time that an ultraviolet aurora has been detected on a celestial object that is not a moon or planet.

According to the space agency: "It is the first time such electromagnetic emissions in the far-ultraviolet have been documented on a celestial object other than a planet or moon."

Launched in 2004, Rosetta is the space exploration's most travelled comet hunter. It orbited comet 67P/Churyumov-Gerasimenko (67P/C-G) from August 2014 "until its dramatic end-of-mission comet landing" in September 2016.

According to Nasa, the data reveal that 67P/C-G's emissions are auroral. The findings were published in the journal Nature Astronomy.

"Electrons streaming out in the solar wind - the stream of charged particles flowing out from the Sun - interact with the gas in the comet's coma, breaking apart water and other molecules. The resulting atoms give off a distinctive far-ultraviolet light. Invisible to the naked eye, far-ultraviolet has the shortest wavelengths of radiation in the ultraviolet spectrum," Nasa said.

The space agency further said that "exploring the emission of 67P/C-G will enable scientists to learn how the particles in the solar wind change over time, something that is crucial for understanding space weather throughout the solar system".

According to Nasa, the northern or southern lights, also called aurora, are "generated when electrically charged particles, speeding from the Sun hit the upper atmosphere to create colourful shimmers of green, white, and red". However, this is the case on Earth.

Elsewhere in the solar system, Jupiter and some of its moons, as well as other planets like Saturn, Uranus, Neptune, and even Mars - all have showcased their own version of northern lights. "But the phenomena had yet to be documented in comets," Nasa said.

Continued here:

In a first, scientists discover comet having own northern lights - India Today

EMA starts rapid review of Bluebird’s gene therapy for rare disease CALD – – pharmaphorum

Bluebird bio could be just a few months away from approval of its gene therapy for rare disease cerebral adrenoleukodystrophy (CALD) in the EU, after the EMA started an accelerated review.

If approved, Lenti-D (elivaldogene autotemcel or eli-cel) could transform the prospects of people with CALD, the most severe form of the neurodegenerative disease ALD that usually emerges in boys during early childhood and causes physical and mental disabilities as well as behavioural problems.

Around 40% of patients develop the cerebral form of ALD, which in turn affects around one in 17,000 live births.

A few weeks ago, Bluebird reported new data from the phase 2/3 STARBEAM trial of Lenti-D which showed that 87% of CALD patients were still alive and free of major functional disabilities after at least two years follow-up.

The EU filing comes ahead of a filing for eli-cel in the US, which Bluebird says should take place sometime towards the middle of next year, having been delayed by the coronavirus pandemic.

If approved, eli-cel would provide a one-shot treatment for CALD, holding back the progressive breakdown in the protective myelin that sheathes neurons.

It would be the first alternative to a stem cell transplant to treat the disease, a therapy that can provide significant improvements and even halt progression in some patients if given early enough.

However it requires high-dose chemotherapy to destroy the bone marrow, and that poses significant risks to patients in its own right, and can also lead to graft-versus-host disease, a potentially life-threatening complication in which the bone marrow donors immune cells attack the recipients cells and tissues.

CALD is caused by mutations in the ABCD1 gene located on the X chromosome, which provides instructions for the production of the ALD protein.

ALD protein is needed to clear toxic molecules called very long-chain fatty acids (VLCFAs) in the brain, and if mutated causes the VLCFAs to accumulate and damage the myelin sheath.

Using eli-cel, the patients own stem cells are modified in the lab to produce a working version of the ABCD1 gene, producing functional ALD protein that can help to flush VLCFAs from the body.

CALD is a devastating disease, often marked by rapid neurodegeneration, the development of major functional disabilities, and eventual death, said Gary Fortin, head of severe genetic disease programmes at Bluebird.

If approved, eli-cel would represent the first therapy for CALD that uses a patients own haematopoietic stem cells, potentially mitigating the risk of life-threatening immune complications associated with transplant using cells from a donor, he added.

Aside from STARBEAM, which will follow treated patients for up to 15 years, Bluebird is also conducting the phase 3 ALD-104 trial of eli-cel in CALD, which is due to generate results in 2024.

The EU filing for eli-cel comes shortly after Bluebirds development partner received a 27 March 2021 FDA review date for anti-BCMA CAR-T cell therapy ide-cel, a potential therapy for multiple myeloma.

The biotech already has approval in Europe for Zynteglo, a gene therapy for haematological disease beta thalassaemia, and is due to file its related therapy LentiGlobin for sickle cell disease next year. The two therapies have been tipped to generate $1.5 billion-plus in peak sales by some analysts.

Go here to see the original:

EMA starts rapid review of Bluebird's gene therapy for rare disease CALD - - pharmaphorum

American Gene Technologies to Present at 2020 Virtual Cell & Gene Meeting on the Mesa – GlobeNewswire

CSO C. David Pauza, Ph.D. Presents on Cell and Gene Therapy for HIV Disease

Chief Science Officer C. David Pauza, Ph.D. Presents At the Intersection of Genetic Medicine and Immunotherapy: Clinical Experience with a Cell and Gene Therapy for HIV Disease

ROCKVILLE, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) -- AmericanGene Technologies(AGT)a cutting-edge cell and gene therapy company in Rockville, Maryland announced today that CEO Jeff Galvin will present at the annual Cell & Gene Meeting on the Mesa. The meeting will be held virtually October 12-16. Galvins presentation will highlight the company's technology, including AGT103-T, a therapeutic intended to cure HIV, which is scheduled to begin Phase 1 clinical trials this month.

Specifics of AGTs clinical trial can be found at https://clinicaltrials.gov/ct2/show/NCT04561258, and details of the HIV therapy intended to cure the disease are on the AGT web site.

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a five-day virtual conference featuring more than 120 presentations from the leading public and private companies. These presentations will highlight the most exciting technical and clinical achievements from the past 12 months in cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies. The meeting also includes over 100 panelists and features speakers taking part in 20 in-depth sessions covering all aspects of cell and gene therapy commercialization.

The following are specific details regarding AmericanGene Technologies presentation at the conference:

Please visit http://www.meetingonthemesa.com for full information including registration. Complimentary attendance at this event is available for accredited investors and members of the media. Investors should contact Laura Stringham at lstringham@alliancerm.org and interested media should contact Kaitlyn Dupont at kdupont@alliancerm.org. The event hashtag is #CGMOM20.

About American Gene Technologies (AGT)

AmericanGene Technologies(AGT)is a gene and cell therapy company with a proprietary gene-delivery platform for rapid development of cell and gene therapies. AGTs mission is to transform peoples lives by designing highly effective therapeutics to cure infectious diseases, cancers, and inherited disorders. AGT has received three patents for the technology used to make the AGT103-T cell product and ten patents for its uniqueimmuno-oncology approachto stimulategamma-delta () T cellsto destroy a variety of solid tumors. The company has also developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. AGT's treatment for PKU has been grantedOrphan Drug Designationby the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2021.

More information is available on:

Website - http://www.americangene.comLinkedIn - LinkedInTwitter -@americangeneFacebook -@amerigeneInstagram -@americangenetechnologies

American Gene Technologies Contacts:

C. Neil Lyons, Chief Financial OfficerPhone: (301) 337-2269Email:info@americangene.comwww.americangene.com

Sasha Whitaker, Digital Marketing and CommunicationsPhone: (301) 337-2100Email:swhitaker@americangene.comwww.americangene.com

A video is available at the following link:https://www.globenewswire.com/NewsRoom/AttachmentNg/2623868c-a33f-49c1-bc46-0c114cbd1d83

See the original post here:

American Gene Technologies to Present at 2020 Virtual Cell & Gene Meeting on the Mesa - GlobeNewswire

Unchained Labs launches the ultimate gene therapy tool; tackle AAV titer, empty/full ratio and more with Stunner! – PRNewswire

PLEASANTON, Calif., Oct. 6, 2020 /PRNewswire/ -- Unchained Labs, the life sciences company that's all about getting researchers the right tool for the job, launched its new gene therapy quantification application on Stunner today. Stunner is the first platform that gives researchers a full read-out on how many AAV capsids they have, how many are packed with DNA and if there is aggregation in less than a minute using only 2 L of sample.

Adeno-associated viruses (AAVs) used in gene therapies are hard to manufacture and tough to characterize. Researchers need to be able to quickly and accurately measure their capsid titer, and how many of them are full of DNA they are supposed to deliver to cells. Other methods that gather this info require labels, dyes, reagents, standard curves or use a lot of sample. Pulling it all together is a big lift and takes way too long with existing technologies.

Stunner makes AAV titer a snap. Researchers just pipette 2 L of their sample, up to 96 samples per run, and then Stunner takes it from there. UV/Vis measures the total protein and DNA in the sample. Dynamic light scattering identifies AAV capsids based on their size and checks for aggregation. Stunner then combines all this information to provide an accurate titer and empty/full ratio.

"Gene therapy researchers are hungry for better tools and Stunner delivers all the data they need," said Taegen Clary, VP of Marketing at Unchained Labs. "No other instrument quantifies AAV capsids, both full and empty, and can see aggregates. These complex molecules demand that traditional techniques be reimagined or combined to provide better insights, and with Stunner's AAV application we've done both."

About Unchained LabsHere's the deal. We're all about helping researchers break free from tools that just don't cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That's our mantra, our promise and we own it. We're located in Pleasanton, CA and can be found online at http://www.unchainedlabs.com.

Contact:Taegen ClaryVP of Marketing, Unchained Labs[emailprotected]925.587.9806

SOURCE Unchained Labs

http://www.unchainedlabs.com

Go here to see the original:

Unchained Labs launches the ultimate gene therapy tool; tackle AAV titer, empty/full ratio and more with Stunner! - PRNewswire

Smartphone-connected pacemaker devices, experimental gene therapy among top 10 innovations at annual event – BioWorld Online

As with many conferences, the Cleveland Clinics 2020 Medical Innovation Summit went virtual this year. Still, the event featured the hotly anticipated top 10 list of innovations for 2021 that saw a range of therapies, including options for arrhythmias and gene therapy for hemoglobinopathies.

Usually, the event sees all innovations presented in a single session, but the top three were highlighted on their own.

Ranked in order of expected importance, the list was led by gene therapy for hemoglobinopathies, which are genetic disorders affecting the structure or production of the hemoglobin molecule. The most common hemoglobinopathies include sickle cell disease and thalassemia. Now, there is an experimental gene therapy that could help patients make functional hemoglobin molecules.

This is a genetic disease that affects more than 20 million people worldwide, said Rabi Hanna, department chair, pediatric hematology, oncology, & blood & marrow transplantation in highlighting the problem. Of note, sickle cell disproportionally affects the Black community. Only three medications have been approved in the past 50 years.

If adopted, this therapy could lead to a cure a very dramatic development. Hanna noted that many companies are in phase III, with one applying for approval and receiving breakthrough designation. He hopes the U.S. FDA could recognize such candidates in the next year.

That was followed by a medication for primary-progressive multiple sclerosis (MS), which affects about 15% of people with the disease. The FDA has approved a therapeutic monoclonal antibody with a novel target, namely the primary-progressive population.

For the first time we have treatment for all forms of MS, explained Adrienne Boissy, chief experience officer at the Cleveland Clinic.

Patients with this form of MS have not had a treatment in the past. This specific treatment is meant to impact the disease itself, both the MRI appearance in this disease as well as functional measures that matter for the patient, like walking and being able to maintain the life that they want to have at the fullest with this treatment.

Coming in third was smartphone-connected pacemaker devices, which are used to prevent or correct arrhythmias. These innovations aim to help in the disconnect between patients and their cardiac treatment. When paired with a mobile app, patients can gain greater insight into health data from the pacemakers. At the same time, the devices can transmit health information to physicians.

Around the world, we have millions of patients walking with pacemakers and defibrillators, and its important to know that remote monitoring of these devices is an essential part of the care of these patients, explained Khaldoun Tarakji. Much data shows that having this leads to better outcomes, perhaps through the early detection of arrhythmias. Still, adoption and adherence have remained suboptimal, he noted.

Typically, remote monitoring has taken place via bedside monitor. Patients must be in close contact with these devices. Now, a smartphone or tablet can act as that monitor, transmitting data from anywhere.

Following that innovation was a treatment for cystic fibrosis, which is caused by a defective cystic fibrosis transmembrane conductance regulator (CFTR) protein. A class of drugs called CFTR modulators correct the proteins action, but medications developed before 2019 only were effective in a subset of people with certain mutations. However, last October, the FDA approved a new option that provides relief for patients with the most common CF gene mutation (F508 del), which is estimated to represent 90% of individuals living with the disease.

Elexacaftor/tezacaftor/ivacaftor is a fixed-dose combination medication of CFTR modulators and chloride channel openers approved for use in those patients with CF who have at least one F508del mutation in the CFTR gene.

Definitely a game changer, confirmed Elliott Dasenbrook, director, Adult Cystic Fibrosis Program, Cleveland Clinic, when asked about the class of drugs. This new class of medications the modulators help the protein channel actually, its misfolded as a result of the genetic mutations, so it helps correct that misfolding and it also helps move it throughout the cell so that it can get to the membrane, where it actually functions.

Holding the number five spot was a universal hepatitis C treatment. While this disease has serious consequences, there is no vaccine, and patients must take medication. Many treatments led to adverse side effects or only were effective for certain genotypes of the disease. However, a fixed-dose combination medication holds hope for these patients. More than 90% effective for hepatitis C genotypes one through six, the therapy represents an effective option for a wider scope of patients.

Coming in next is bubble CPAP (b-CPAP) for increased lung function in premature babies. Premature babies with infant respiratory distress syndrome (IRDS) often require ventilation. Those with IRDS commonly are administered a surfactant during mechanical ventilation, a practice that can cause lasting lung injury. B-CPAP is a noninvasive ventilation strategy, delivering continuous positive airway pressure to newborns to maintain lung volumes during exhalation.

The procedure can stimulate the lung to grow while minimizing the injury to the lung, explained Hany Aly, department chair, neonatology, Cleveland Clinic.

Unsurprisingly, telemedicine, which played a big role during the ongoing COVID-19 pandemic, made the list. Specifically, the clinic highlighted state and national regulators actions in reducing telehealth adoption barriers. Their actions permitted more widespread telehealth adoption.

COVID was a complete disruptor, and it was a disruptor that we needed, said Beri Ridgeway, associate chief of staff & chair, obstetrics, Gynecology & Women's Health Institute, Cleveland Clinic. Policy is so critical, and I believe it was one of the barriers that prevented us from taking telehealth to the next level. By taking steps on the state and federal levels in March to remove these barriers, patients benefitted. Changes came in terms of who could see patients, by what platform to include chat functions on the phone and coverage. By April, 90% of clinicians were using some sort of telehealth, it was noted.

The number eight spot was held by a vacuum-induced uterine tamponade device for postpartum hemorrhage, which affects about 1% to 5% of women who give birth. Those who experience this condition face possible blood transfusions and emergency hysterectomy. Nonsurgical interventions have involved balloon devices that expand the uterus while compressing the site of bleeding. However, a vacuum-induced uterine tamponade has caught the attention of the medical community. It is a low-tech solution that is potentially translatable to developing countries with low resource availability.

I think this is going to replace the use of the balloon compression devices for control of hemorrhage, said Edward Chien, department chair, obstetrics & gynecology, Cleveland Clinic.

In September, Alydia Health said it had received U.S. FDA clearance of the Jada system, which is designed to rapidly control and treat postpartum hemorrhage and abnormal postpartum uterine bleeding. At the same time, it announced the publication of its pivotal PEARLE study in Obstetrics & Gynecology, which demonstrated that Jada is safe and highly effective in using vacuum to control postpartum bleeding.

Holding down the ninth spot is PARP inhibitors for prostate cancer, a condition one in nine men will be diagnosed with in his lifetime. PARP inhibitors pharmacological inhibitors for cancer treatment block proteins called PARP that help repair damaged tumor DNA in individuals with BRCA1 and BRCA2 gene mutations.

The PARP inhibitors rucaparib and olaparib have been demonstrated to delay the progression of prostate cancer in men with refractory cancer and BRCA mutations. Both were approved for the prostate cancer indication in May.

While not a new treatment in cancer overall, PARP inhibitors could prove very helpful for men with this condition. And while the gynecological field has led the way, this option has been considered for years in prostate cancer, said Moshe Ornstein, associate staff, Hematology & Medical Oncology Cleveland Clinic. They will be appropriate for patients who have specific mutations in their DNA damage repair pathways.

Finally, coming in at number 10 was immunologics for migraine prophylaxis. While a host of products have tried to help this condition, nothing was directed solely for migraines. In 2018, new medications were developed for migraine sufferers that blocked the activity of a molecule called calcitonin gene-related peptide. This medication is the first to be specifically designed for the preventive treatment of migraine.

The first three medications approved for the prevention of both chronic and episodic migraines are erenumab, galcanezumab, and fremanezumab. These options were approved by the FDA in May and September 2018, respectively. They are given as once-monthly injections and are extremely well-tolerated. For most people, there are few adverse reactions aside from some pain at the injection site.

Its an exciting time to be in headache medicine. Its been years since weve had any type of new therapeutics to treat this disorder, MaryAnn Mays, director, Neurology Residency Program at the Cleveland Clinic, said.

View original post here:

Smartphone-connected pacemaker devices, experimental gene therapy among top 10 innovations at annual event - BioWorld Online

CellGenix Completes Facility Expansion to Stay Ahead of the Increasing Demand for GMP Raw Materials – b3c newswire

FREIBURG, Germany, October 08, 2020 / B3C newswire / -- CellGenix GmbH, a pioneer for GMP grade reagents and a leading global supplier of high quality raw and ancillary materials for cell and gene therapies, announces the completion of the second phase of their facility expansion. CellGenix has reconstructed and expanded their production facility for cytokines and implemented a state-of-the art automated filling and freeze-drying line.

By implementing an automated filling and freeze-drying line and increasing bulkware production footprint, finished product capacity for cytokines is substantially increased. This continues to enable CellGenix to meet the fast-growing demand for critical raw and ancillary materials as more customers reach late-stage clinical development and commercialization of their cell and gene therapies. Scaling up from phase I or II clinical trials to large-scale commercial manufacturing, the demand for GMP cytokines often rises by several magnitudes. Consequently, a secure supply chain is imperative. A delay in delivery or change in product quality could lead to delays in production, not only increasing costs but also putting precious patient samples in jeopardy.

The newly designed and expanded facility enables CellGenix to streamline their production processes. The automated filling process also provides increased accuracy and reduced risks, which further increases the safety of their preclinical and GMP cytokines. The automated filling, stoppering and capping system (operates under an Open Restricted Area Barrier System (ORABS) and) is compliant with EU GMP Annex 1 for the manufacture of sterile medicinal products, also taking into account the new version which is currently under revision.

In a first expansion phase in 2018 CellGenix added additional space and personnel in its quality control, R&D, logistics and warehouse departments. By finishing both expansion phases, CellGenix has further strengthened their position as a leading supplier for large scale manufacturing in the cell and gene therapy space.

The expansion of our facility is a result of the robust, sustainable, and profitable growth, generated by long standing and trustful customer relationships we achieved over many years. CellGenix is now well prepared for the future growth of the cell and gene therapy market. It supports our goal to further establish CellGenix as a key provider in the fight against disease, preferred supplier or raw and ancillary materials and trusted partner for large scale manufacturing of cell and gene therapies. Felicia Rosenthal, Chief Executive Officer at CellGenix.

About CellGenixCellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. CellGenix develops, manufactures and markets human cytokines, growth factors, and other recombinant cell culture components in preclinical and GMP quality as well as proprietary serum-free media for further manufacturing of ATMPs. As a former ATMP developer and manufacturer, in more than two decades CellGenix gained in-depth cell processing knowledge and superior regulatory expertise. With this unique background, CellGenix understands the high requirements their customers are facing during product development and the regulatory approval process. To meet the increasing demand of GMP quality raw materials for ATMP manufacturing CellGenix has recently expanded manufacturing capacity, built additional R&D and QC laboratories, and warehouse space. The upgrade also introduced state-of-the-art, automated, large-scale capacities for recombinant protein products in the existing GMP facilities. CellGenix is headquartered in Freiburg, Germany and operates a subsidiary near Boston in Portsmouth, USA.

Contact

CellGenixFelicia M. RosenthalCEOThis email address is being protected from spambots. You need JavaScript enabled to view it. Am Flughafen 1679108 Freiburg, Germany

Keywords: Cytokines; Genetic Therapy; Cell- and Tissue-Based Therapy; Regenerative Medicine; Culture Media, Serum-Free; Indicators and Reagents; Manufactured Materials; Cell Culture Techniques; Freeze Drying

Published by B3C newswire

Continue reading here:

CellGenix Completes Facility Expansion to Stay Ahead of the Increasing Demand for GMP Raw Materials - b3c newswire

Cleveland Clinic Names Top 10 Medical Innovations; Sickle Cell Therapy Tops the List – HealthLeaders Media

The innovation experts at Cleveland Clinic have peered into their crystal ball and pronounced the most profound medical advancements that will impact the care and treatment of patients in the coming year.

During the closing session of the 2020 Cleveland Clinic Medical Innovation Summit, the 18th year the conference has been held, Cleveland Clinic Innovations shared its annual list of top 10 medical innovations. The breakthrough technologies were selected by a committee of Cleveland Clinic subject matter experts, led by Will Morris, MD, executive medical director, Cleveland Clinic Innovations, and Akhil Saklecha, MD, managing director, Cleveland Clinic Ventures.

1. Gene Therapy for Hemoglobinopathies

Experimental gene therapy gives new hope to those suffering from hemoglobinopathies, genetic disorders responsible for sickle cell disease and thalassemia. Through treatment, those with these conditions have the potential ability to make functional hemoglobin molecules, reduce the presence of sickled blood cells or ineffective red blood cells in thalassemia, and prevent associated complications.

2. Novel Drug for Primary-Progressive Multiple SclerosisA new, U.S. Food and Drug Administration (FDA)-approved therapeutic monoclonal antibody with a novel target is the first and only multiple sclerosis (MS) treatment for 15% of primary-progressive patients, who experience gradual onset and steady progression of signs and symptoms. In those with MS, the immune system attacks the fatty protective myelin sheath that covers the nerve fibers, causing communication problems between the brain and the rest of the body that can result in permanent damage or deterioration and eventual death.

3. Smartphone-Connected Pacemaker Devices

Remote monitoring of implantable pacemakers and defibrillators traditionally occurs through a bedside console that transmits data to the physician. Yet many patients don't understand how it functions, and adherence to remote monitoring has been suboptimal. New Bluetooth-enabled pacemaker devices used in conjunction with a mobile app, offer a convenient new method to transmit data, while also providing patients greater insight into their health status.

4. New Medication for Cystic Fibrosis

A new combination drug, approved by the FDA in October 2019, provides relief for patients with the most common cystic fibrosis gene mutation (F508 del), estimated to represent 90% of individuals living with the disease. Medications developed prior to last year had only been effective in a subset of people with certain mutations.

5. Universal Hepatitis C Treatment

A new, approved fixed-dose combination medication has vastly improved hepatitis C treatment. More than 90% effective for hepatitis C genotypes one through six, the therapy represents an effective option for a wider scope of patients. With no vaccine for the hepatitis C virus, patients have been limited to medication, but many treatments were accompanied by adverse side effects or only effective for certain genotypes of the disease.

6. Bubble CPAP for Increased Lung Function in Premature Babies

Newborns with infant respiratory distress syndrome now have access to a safer method of ventilation though b-CPAP, a non-invasive ventilation strategy. Unlike mechanical ventilation, which administers a surfactant that can cause lasting lung injury, b-CPAP maintains lung volumes during exhalation through oscillating, rather than constant pressure, minimizes physical trauma, and stimulates lung growth when administered over a prolonged period.

7. Increased Access to Telemedicine through Novel Practice and Policy Changes

While telehealth technologies and initiatives have been around for years, COVID-19 forced them into the spotlight and stimulated widespread adoption. "Since March, state and federal regulators have moved quickly to reduce telehealth adoption barriers, understanding that these tools can speed access to care while protecting healthcare workers and community members," according to Cleveland Clinic. "These measures opened the floodgates for telehealth, allowing for new programs and the expansion of existing networks."

8. Vacuum-Induced Uterine Tamponade Device for Postpartum Hemorrhage

A low-tech solution is now part of the arsenal to fight postpartum hemorrhage (PPH). Vacuum-induced uterine tamponade uses negative pressure created inside the uterus to collapse the bleeding cavity, causing the muscle to close off the hemorrhaging vessels. The device represents another minimally invasive tool that is potentially translatable to developing countries with minimal resources.

9. Prostate Cancer PARP Inhibitors

Previously known for their success in treating womens cancers, two PARP inhibitors, which block proteins that help repair damaged tumor DNA in people with BRCA1 and BRCA2 gene mutations, were approved for prostate cancer treatment in May. These pharmacological agents have been demonstrated to delay the progression of prostate cancer in men with refractory cancer and DNA repair pathway mutations.

10. Immunologics for Migraine Prophylaxis

New medications were developed in 2018 help head off migraine pain by blocking activity of the calcitonin gene-related peptide (CGRP) molecule, which spikes during these headaches. In 2020 this FDA-approved class of medication became the first actively prescribed therapeutic for preventative treatment of migraines, which affect an estimated 12% of the U.S. adult population.

More information about the these innovations, including videos and year-by-year comparisons is available on the website.

Mandy Roth is the innovations editor at HealthLeaders.

Originally posted here:

Cleveland Clinic Names Top 10 Medical Innovations; Sickle Cell Therapy Tops the List - HealthLeaders Media

Investigational Gene Therapy for Phenylketonuria Gets Fast Tracked – Monthly Prescribing Reference

The Food and Drug Administration (FDA) has granted Fast Track designation to the investigational gene therapy BMN 307 (BioMarin Pharmaceutical) for the treatment of patients with phenylketonuria (PKU).

BMN 307 is an adeno-associated virus type 5 (AAV5)-phenylalanine hydroxylase (PAH) gene therapy designed to normalize blood phenylalanine (Phe) concentration levels in patients with PKU by inserting a correct copy of the PAH gene into liver cells.

The Company recently initiated an open-label phase 1/2 study (PHEARLESS) to evaluate the safety, efficacy and tolerability of a single intravenous administration of BMN 307 in adults with PKU with PAH deficiency. The study will assess whether a single dose of treatment can restore natural Phe metabolism, increase plasma Phe levels, and enable a normalization of diet in patients with PKU.

Fast Track designation combined with our ability to conduct our clinical studies incorporating material manufactured using a commercial-ready process will further facilitate rapid clinical development of BMN 307 gene therapy, said Hank Fuchs, MD, President, Worldwide Research and Development at BioMarin. We are looking forward to working closely with the FDA, as well as other health agencies, to evaluate the safety and efficacy of this promising investigational gene therapy as we continue our unwavering 15-year commitment to advance the standard of care for people with PKU.

The FDAs Fast Track designation allows for expedited review of therapies that are meant to treat serious or life-threatening conditions. Generally, the designation is granted to drugs that are expected to have an impact on factors such as survival and daily functioning.

For more information visit biomarin.com.

BioMarin, pioneer in phenylketonuria (PKU) and gene therapy, receives FDA Fast Track designation for PKU investigational gene therapy, BMN 307. https://www.prnewswire.com/news-releases/biomarin-pioneer-in-phenylketonuria-pku-and-gene-therapy-receives-fda-fast-track-designation-for-pku-investigational-gene-therapy-bmn-307-301144678.html. Accessed October 5, 2020.

Read more:

Investigational Gene Therapy for Phenylketonuria Gets Fast Tracked - Monthly Prescribing Reference

Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual Meeting on the Mesa – GlobeNewswire

BURLINGTON, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc.(Nasdaq:FLXN) announced today thatAdam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the annual 2020 Cell & Gene Virtual Meeting on the Mesa. Dr. Muzikant will provide a review of FX201, an investigational, intra-articular, IL-1Ra gene therapy product candidate in clinical development for the treatment of osteoarthritis (OA).

The Company is conducting an open-label, Phase 1 dose-escalation trial evaluating the safety and tolerability of FX201 in patients with knee OA. The trial is intended to test low, mid and high doses of FX201 in cohorts of five to eight patients. Following the completion of the low-dose cohort and data review by an independent Drug Monitoring Committee, the trial has advanced to enrolling the mid-dose cohort. Data from the study are anticipated in 2021.

Organized by theAlliance for Regenerative Medicine, the 2020 Cell & Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days beginning on October 12. The conference will feature more than 120 presentations by leading public and private companies highlighting the technical and clinical achievements in the areas of cell therapy, gene therapy, gene editing, tissue engineering and broader regenerative medicine technologies.

About FX201FX201 (humantakinogene hadenovec) is a novel, clinical-stage, intra-articular gene therapy product candidate which utilizes a helper-dependent adenovirus (HDAd) vector based on human serotype 5 (Ad5) that is designed to transfer a gene to cells in the joint to produce an anti-inflammatory protein, interleukin-1 receptor antagonist (IL-1Ra), under the control of an inflammation-sensitive promoter. Inflammation is a known cause of pain, and chronic inflammation is thought to play a major role in the progression of OA. By persistently suppressing inflammation, Flexion believes FX201 holds the potential to provide long-term pain relief and functional improvement, and to modify disease progression.

About Flexion TherapeuticsFlexion Therapeutics(Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA, the most common form of arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Visitflexiontherapeutics.com.

Forward-Looking Statements This release contains forward-looking statements that are based on the current expectations and beliefs of Flexion. Statements in this press release regarding matters that are not historical facts, including, but not limited to, statements relating to the future of Flexion; timing and plans with respect to the Phase 1 clinical trial of FX201; and the potential therapeutic and other benefits of FX201, are forward looking statements. These forward-looking statements are based on managements expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the fact that the impacts and expected duration of the COVID-19 pandemic are uncertain and rapidly changing; the risk that we may not be able to maintain and enforce our intellectual property, including intellectual property related to FX201; risks related to clinical trials, including potential delays, safety issues or negative results; and other risks and uncertainties described in our filings with the Securities and Exchange Commission (SEC), including under the heading Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the SEC on August 5, 2020 and subsequent filings with the SEC. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of the statements. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

Contacts:

Scott YoungVice President, Corporate Communications & Investor RelationsFlexion Therapeutics, Inc.T: 781-305-7194syoung@flexiontherapeutics.com

Julie DownsAssociate Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc.T: 781-305-7137jdowns@flexiontherapeutics.com

Read the rest here:

Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual Meeting on the Mesa - GlobeNewswire

Cancer Gene Therapy Market 2020 by industry trends, statistics, key companies growth and regional forecast – News by Decresearch

Cancer Gene Therapy Market report offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and industry challenges.

Growing prevalence of cancer with rising mortality rates will augment cancer gene therapy industry forecast in the coming years. Cancer therapies incorporated with genetically modified genes ai in blocking the growth of the tumors.

Efficient PCR and isothermal amplification technologies for detecting mutations and CRISPR gene editing tools are some technical developments. These advancements have led to innovations and ensured availability of advanced cancer gene therapies driving the industry trends.

Request for a sample copy of this report @https://www.decresearch.com/request-sample/detail/763

Estimates have stated that the global cancer gene therapy market value is likely to cross an annual valuation of USD 2.5 billion by 2025.

Technological developments are majorly fueling cancer gene therapy growth. Genetically modified genes which block tumor growth have been incorporated into recent cancer therapies. Efficient isothermal amplification techniques and PCR technology are transforming the way gene mutations are detected. Recent launch of CRISPR gene editing tools is claimed to help enhance the process of gene therapy development. These innovations and advancements in technology are anticipated to propel cancer gene therapy industry size.

The in-vivo segment is estimated to witness about 22% growth over the forecast period owing to its multiple offered benefits. In-vivo gene therapy consists of direct delivery of therapeutic genes into the target cell, a process which has shown effective results in cancer treatment. Viral vectors are delivered using in-vivo gene therapy which help in stopping the activity of tumor inducing genes and has exhibited positive results in clinical trials.

Biopharmaceutical firms held approximately 48% of the industry revenue share in 2018. Major firms such as Roche and Novartis are working on cancer gene therapies that have high adoption rate of both non-viral and viral vectors. These firms are also carrying out clinical trials that are favoring the demand for such vectors, consequently driving market growth.

Broadening awareness regarding the availability of advanced cancer therapies have stimulated the market for cancer gene therapy in China. Government initiatives and funds have encouraged researchers to carrying out extensive R&D activities linked to cancer gene therapy.

Meanwhile, on a global landscape, companies like Vigene Biosciences, Cobra, Uniqure, Sirion Biotech, Bluebird Bio, Caribou, Ziopharm, Finvector, Cellectis and Sarepta Therapeutics are leading the cancer gene therapy market. These firms are focusing on enhancing their market position through business strategies such as product launches, mergers and acquisitions, among others.

Browse full table of contents (TOC) of this report @ https://www.decresearch.com/toc/detail/cancer-gene-therapy-market

Partial Chapter of the Table of Content

Chapter 4. Cancer Gene Therapy Market, By Type

4.1. Key segment trends

4.2. Ex-vivo

4.2.1. Market size, by region, 2014 2025 (USD Million)

4.3. In-vivo

4.3.1. Market size, by region, 2014 2025 (USD Million)

Chapter 5. Cancer Gene Therapy Market, By Product

5.1. Key segment trends

5.2. Viral vectors

5.2.1. Market size, by region, 2014 2025 (USD Million)

5.2.2. Adenoviruses

5.2.2.1. Market size, by region, 2014 2025 (USD Million)

5.2.3. Lentiviruses

5.2.3.1. Market size, by region, 2014 2025 (USD Million)

5.2.4. Retrovirus

5.2.4.1. Market size, by region, 2014 2025 (USD Million)

5.2.5. Adeno associated virus

5.2.5.1. Market size, by region, 2014 2025 (USD Million)

5.2.6. Herpes simplex virus

5.2.6.1. Market size, by region, 2014 2025 (USD Million)

5.2.7. Vaccinia virus

5.2.7.1. Market size, by region, 2014 2025 (USD Million)

5.2.8. Others

5.2.8.1. Market size, by region, 2014 2025 (USD Million)

5.3. Non-viral vectors

5.3.1. Market size, by region, 2014 2025 (USD Million)

5.4. Others

5.4.1. Market size, by region, 2014 2025 (USD Million)

More:

Cancer Gene Therapy Market 2020 by industry trends, statistics, key companies growth and regional forecast - News by Decresearch

Taysha Gene Therapies Partners with Invitae to Enable Rapid Access to Genetic Testing and Earlier Diagnosis of Patients with CNS Disease for Rare and…

Detect Lysosomal Storage Diseases program reduces barriers to genetic diagnosis through sponsored testing for lysosomal storage disorders, including GM2 gangliosidosis

Behind the Seizure program can help accelerate genetic epilepsy diagnosis in children experiencing unprovoked seizures

Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced a partnership with Invitae, a leading medical genetics company, to support Invitaes Detect Lysosomal Storage Diseases (Detect LSDs) and Behind the Seizure programs. The Detect LSDs program enables the rapid diagnosis of lysosomal storage disorders (LSDs), including GM2 gangliosidosis (also known as Tay-Sachs and Sandhoff disease). The Behind the Seizure program is an innovative, cross-company collaboration that supports faster diagnosis for children with epilepsy. The Behind the Seizure program will also support patient identification across Tayshas broad pipeline of gene therapies for which a number of indications have an underlying seizure phenotype.

"Through both initiatives, we are supporting the rapid identification of patients with debilitating diseases, allowing them to gain access to earlier therapeutic interventions. For LSDs, there are more than 50 different disorders with overlapping symptoms, making misdiagnosis common," said RA Session II, Tayshas President, CEO and Founder. "Likewise, more than 50% of epilepsies have a genetic basis. When a patient presents with seizures, genetic testing may help identify more than 100 underlying, often rare conditions. We are proud to support these initiatives to help patients gain timely access to natural history studies, clinical trials, and ultimately disease-modifying therapies."

Eligible individuals suspected of having an LSD or epilepsy will gain access to genetic testing and counseling at no charge through these programs. The Detect LSDs program will help identify individuals who are eligible for Tayshas study evaluating TSHA-101 in patients with GM2 gangliosidosis, expected to enter the clinic later this year. The Behind the Seizure program will enable patient identification across Tayshas broad pipeline of indications, some of which have an underlying seizure phenotype, and rapid enrollment into natural history studies and clinical trials.

Story continues

"Increasing access to genetic testing can support earlier diagnosis of neurodegenerative diseases, which in turn enables clinicians to provide precision therapies sooner and better overall outcomes," said Robert Nussbaum, M.D., Chief Medical Officer of Invitae. "These unique, cross-company collaborations have been shown to help increase access to testing and reduce time to diagnosis. We are pleased Taysha has joined us in helping increase access to testing for children impacted by neurodegenerative conditions."

Additional details, as well as terms and conditions of the Detect LSDs program, can be found at https://www.invitae.com/en/detectLSDs/. To learn more about the Behind the Seizure program, please visit https://www.invitae.com/en/behindtheseizure/.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our teams proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platforman engine for potential new cureswith a goal of dramatically improving patients lives. More information is available at http://www.tayshagtx.com.

About Invitae

Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning or implying the conduct or timing of our partnership with Invitae and our planned clinical trial of TSHA-101 for the treatment of GM2 gangliosidosis, the potential of our product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission filings, including in our prospectus dated September 23, 2020, as filed with the Securities and Exchange Commission ("SEC") on September 24, 2020, pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which is available on the SECs website at http://www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005450/en/

Contacts

Company Contact: Niren Shah, PharmD, MBATaysha Gene TherapiesNshah@tayshagtx.com

Media Contact: Carolyn HawleyCanale Communicationscarolyn.hawley@canalecomm.com

See more here:

Taysha Gene Therapies Partners with Invitae to Enable Rapid Access to Genetic Testing and Earlier Diagnosis of Patients with CNS Disease for Rare and...

Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia -…

Gosselies, Belgium, 5 October 2020, 7am CEST BONE THERAPEUTICS(Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, Link Health Pharma Co., Ltd (Link Health) and Shenzhen Pregene Biopharma Company, Ltd (Pregene) today announce the signing of an exclusive license agreement for the manufacturing, clinical development and commercialization of Bone Therapeutics allogeneic, off-the-shelf, bone cell therapy platform ALLOB in China (including Hong Kong and Macau), Taiwan, Singapore, South Korea, and Thailand.

Under the agreement, Bone Therapeutics is eligible to receive up to 55 million in development, regulatory and commercial milestone payments including 10 million in upfront and milestone payments anticipated in the next 24 months. Bone Therapeutics is also entitled to receive tiered double-digit royalties on annual net sales of ALLOB. Bone Therapeutics retains development and commercialization rights to ALLOB in all other geographies outside of those covered by this agreement. As a result, Bone Therapeutics will continue to concentrate on its development and commercialization plans for ALLOB in the US and Europe and novel innovative cell-based products globally.

This collaboration between Bone Therapeutics, Link Health and Pregene expands our geographic reach and demonstrates the global commercial potential of ALLOB,said Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics. We already have operational experience in Asia with the Phase III clinical trial of our lead product JTA-004 in Hong Kong. We selected Link Health and Pregene to partner with us in Asia as a result of their expertise in advanced therapeutics and cell therapies, their proven track record of development and commercial implementation in Chinese and Asian markets, and Pregenes well established cell therapy manufacturing capacity. Bone Therapeutics will continue to develop the ALLOB cell therapy platform for other markets while exploring additional partnership opportunities in the U.S. and Europe.

The agreement grants Link Health and Pregene exclusive rights to clinically develop and commercialize ALLOB for the treatment of human bone disorders in Greater China, Taiwan, Singapore, South Korea, and Thailand. All rights for China will be transferred to Pregene and Link Health will gain rights for the remaining countries Bone Therapeutics will share its patented proprietary manufacturing expertise for the expansion and differentiation of bone-forming cells and has the option to sell clinical supplies to Link Health and Pregene in preparation for their clinical development of ALLOB.

This collaboration and license agreement for Bone Therapeutics ALLOB provides a strong addition to our pipeline. ALLOB has demonstrated the potential to reduce the recovery time and stimulate bone growth for a variety of bone conditions, and to have a considerable impact on patients lives,said Yan Song, PhD, Chief Executive Officer of Link Health. It is important for Link Health to collaborate with companies that have strong therapeutic product portfolios and entrepreneurial management. This partnership with Bone Therapeutics is a direct result of our shared commitment to appreciate the enormous potential of cell therapy and regenerative medicine.

Pregene now has a flourishing portfolio of CAR-T cell therapy-based cancer treatments. Bone Therapeutics ALLOB provides anallogeneic, off-the-shelf cell therapy that expands our portfolio of cell therapies to include the sizable commercial potential of orthopedics,said Hongjian Li, Co-founder and Chief Executive Officer of Pregene. We expect to be able to leverage our extensive international cell and gene therapy experience to develop Bone Therapeutics ALLOB platform and subsequently launch products in China and Southeast Asian markets.

ALLOB, an allogeneic and off-the-shelf cell therapy product manufactured through a proprietary, scalable production process, consists of human bone-forming cells derived from cultured bone marrow mesenchymal stem cells of healthy adult donors. In preclinical studies ALLOB has shown to reduce healing time in a delayed-union fracture model by half, and has demonstrated good tolerability and signs of efficacy in two Phase IIa studies for two separate indications. The Companys randomized, placebo-controlled, double-blind Phase IIb clinical trial in patients with difficult tibial fractures has received approval from regulatory authorities in six of the seven planned European countries to date, and is expected to enroll the first patient later this year.

About Link Health Pharma Co., Ltd

Link Health is a leading Chinese pharmaceutical company based in Guangzhou, Southern China, focusing on the development of innovative drugs for unmet medical needs.

Link Health has created a highly professional team with diverse expertise in drug development, medical affairs and regulatory affairs. Leveraging deep understanding of China market, regulatory environment and strong network with global biopharmaceutical companies, Link Health is well positioned to bring innovative drugs to the market efficiently. The company has a drug development pipeline of 5 clinical stage assets and 1 under NDA reviewing in China.

The company has also established a fully owned subsidiary in Amsterdam, the Netherlands. The Dutch office builds and further strengthen collaborations with global pharma/biotech partners and research institutes.

About Pregene Biopharma Co., Ltd

Shenzhen Pregene Biopharma Co. Ltd is a leading enterprise in the cell and gene therapy field with the core technology for industrialization. The companys core team comes from well-known institutions and companies including the Academy of Military Medical Sciences, the University of Toronto, and the US FDA.

Pregene has established the gene editing platform, viral vector and cell production platform, nanobody selection platform and other small to pilot trial manufacturing system, with total investment over 100 million CNY. It has the laboratories and GMP plants for cell and gene therapy of over 10,000 square meter.

The company focuses on the research and development of cell and gene therapy drugs, and participated in the drafting the national standard Considerations for CAR-T Cell Quality Study and Non-clinical Evaluation issued by the National Institutes for Food and Drug Control in June 2018. The CAR-T cell therapy for the treatment of multiple myeloma have obtained NMPA IND clearance as the Class I new drug, which is the first in China and fastest in the world using the humanized single domain antibody in CAR construct, and phase I clinical trials are now in progress. Other pipelines such as CAR-T, TCR-T and mRNA drugs for tumors, autoimmune diseases and other indications are in the development at different stages. The company has broad development prospects with the abundant backup technologies.

Looking forward to the future, the company will build the core capacity in one-stop solution for cell and gene therapy drugs, and fulfill the Express of innovative medicine development from drug discovery to clinical products.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement.

Bone Therapeutics core technology is based on its cutting-edge allogeneic cell therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company is ready to start the phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics cell therapy products are manufactured to the highest GMP standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available atwww.bonetherapeutics.com.

For further information, please contact:

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0)71 12 10 00investorrelations@bonetherapeutics.com

For Belgian Media and Investor Enquiries:BepublicCatherine HaquenneTel: +32 (0)497 75 63 56catherine@bepublic.be

International Media Enquiries:Image Box CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20 8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: +33 (0)1 44 71 94 94bone@newcap.eu

For US Media and Investor Enquiries:LHA Investor RelationsYvonne BriggsTel: +1 310 691 7100ybriggs@lhai.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Go here to see the original:

Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia -...

Axovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6th – GlobeNewswire

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the Company will present at upcoming conferences and will announce six-month safety and efficacy data from the second cohort of its AXO-Lenti-PD program the morning of Tuesday, October 6, 2020. Additionally, as previously announced the Company will hold a Parkinsons Disease R&D Day on Friday, October 30.

Information on the upcoming presentations can be found below:

Chardan 4th Annual Genetic Medicines Conference

2020 ARM Virtual Cell and Gene Meeting on the Mesa

AXO-Lenti-PD Parkinsons Disease R&D Day

A live webcast of the presentations will be available in the Events section of Axovant's website at http://www.axovant.com.Replays will be available for approximately 30 days following the conferences.

About Axovant Gene Therapies

Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinsons disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit http://www.axovant.com.

Contacts:

Media & Investors

Parag MeswaniAxovant Gene Therapies Ltd.(212) 547-2523media@axovant.cominvestors@axovant.com

See the original post here:

Axovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6th - GlobeNewswire